Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?

In patients with risk factors for hepatotoxicity (ie, chronic viral hepatitis or liver disease, pregnancy or significant alcohol history) or abnormal baseline LFTs, further monitoring is indicated whilst on treatment. 1 2 In all other cases repeat liver function testing is reserved for patients developing symptoms suggestive of liver dysfunction (fever, malaise, nausea, vomiting, abdominal pain, jaundice or unexplained fatigue). [...]most cases of hepatotoxicity continue to be identified by current guidelines, although HIV co-infection does appear to impact upon both the incidence of hepatotoxicity and the use of the recommended algorithm (where LFT monitoring on treatment is indicated according to symptoms).